fasudil has been researched along with Bone Fractures in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Luo, D | 1 |
| Zhan, J | 1 |
| Hou, Y | 1 |
| Chen, S | 1 |
| Li, X | 1 |
| Lin, D | 1 |
1 other study available for fasudil and Bone Fractures
| Article | Year |
|---|---|
Fasudil enhanced differentiation of BMSCs in vivo and vitro, involvement of P38 signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biomarkers; Bone Marrow Cells; Cell Differen | 2020 |